Compile Data Set for Download or QSAR
Report error Found 8 Enz. Inhib. hit(s) with all data for entry = 12539
Target5-hydroxytryptamine receptor 2A(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  8.30nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM708104(US12173004, Example 1)
Affinity DataKi:  11nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  11nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM708104(US12173004, Example 1)
Affinity DataKi:  22nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

TargetMu-type opioid receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM708104(US12173004, Example 1)
Affinity DataKi:  22nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

TargetD(1A) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  50nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

TargetD(2) dopamine receptor(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  160nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent

TargetSodium-dependent serotonin transporter(Human)
Intra-Cellular Therapies

US Patent
LigandPNGBDBM683053(US12023331, Example 1 | US20240307386, Compound Ex...)
Affinity DataKi:  590nMAssay Description:In general, the results are expressed as a percent of control specific binding:measured⁢specific⁢bindingcontrol⁢specific⁢binding×100and as a percent ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/5/2025
Entry Details
Go to US Patent